Measurement of F2-isoprostanes as an index of oxidative stress in vivo

Free Radical Biology and Medicine

Volumn 28, Issue 4, 2000, Pages 505-513

  Roberts II, L Jackson ^a   Morrow, Jason D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Free radical; Isoprostanes; Lipid peroxidation; Oxidant stress

Indexed keywords

ARACHIDONIC ACID; FREE RADICAL; ISOPROSTANE DERIVATIVE; LIPID HYDROPEROXIDE; MALONALDEHYDE; PROSTAGLANDIN F2;

CONFERENCE PAPER; HUMAN; INJURY; LIPID PEROXIDATION; MEASUREMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN SYNTHESIS; URINARY EXCRETION;

ANIMALS; BIOLOGICAL MARKERS; DINOPROST; HUMANS; LIPID PEROXIDATION; OXIDATIVE STRESS;

ANIMALIA;

EID: 0034652768     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00264-6     Document Type: Conference Paper

References (66)

1. Pryor W.A. On the detection of lipid hydroperoxides in biological samples. Free Radic. Biol. Med. 7:1989;177-178.
2. Halliwell B., Grootveld M. The measurement of free radical reactions in humans. FEBS Lett. 213:1987;9-14.
3. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87:9383-9387; 1990.
4. Taber, D. F.; Morrow, J. D.; Roberts, L. J., II. A nomenclature system for the isoprostanes. Prostaglandins 53:63-67; 1997.
5. 2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA89:10721-10725; 1992.
6. 2-isoprostanes in vitro and in vivo effect of oxygen tension and glutathione. Arch. Biochem. Biophys. 353:1998;160-171.
7. Morrow J.D., Minton T.A., Mukundan C.R., Campbell M.D., Zackert W.E., Daniel V.C., Badr K.F., Blair I.A., Roberts L.J. II. Free radical induced generation of isoprostanes in vivo Evidence for the formation of D-ring and E-ring isoprostanes. J. Biol. Chem. 269:1994;4317-4326.
8. Morrow, J. D.; Awad, J. A.; Wu, A.; Zackert, W. E.; Daniel, V. C.; Roberts, L. J., II. Free radical generation of thromboxane-like compounds (isothromboxanes) in vivo. J. Biol. Chem. 271:23185-23190; 1996.
9. Chen, Y.; Morrow, J. D.; Roberts, L. J., II. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J. Biol. Chem.274:10863-10868; 1999.
10. Brame, C. J.; Salomon, R. G.; Morrow, J. D.; Roberts, L. J., II. Identification of extremely reactive γ-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J. Biol. Chem. 274:13139-13146; 1999.
11. Roberts L.J. II, Morrow J.D. The generation and actions of isoprostanes. Biochim. Biophys. Acta. 1345:1997;121-135.
12. Morrow, J. D.; Roberts, L. J., II. The isoprostanes: Unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36:1-21;1997.
13. 2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 300:1998;3-12.
14. Granstrom E., Kindahl H. Radioimmunoassay of prostaglandins and thromboxanes. Adv. Prostaglandin Thromboxane Leukot. Res. 5:1978;119-210.
15. Proudfoot J., Barden A., Mori T.A., Burke V., Croft K.D., Beilin L.J., Puddey I.B. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidationa comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal. Biochem. 272:1999;209-215.
16. Richelle M., Turini M.E., Guidoux R., Tavazzi I., Metairon S., Fay L.B. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett. 459:1999;259-262.
17. 2-isoprostanes and malondialdehyde in peroxidizing rat liver microsomes. Biochem. Pharmacol. 47:1994;1173-1177.
18. Burk R.F. Glutathione-dependent protection by rat liver microsomal protein against lipid peroxidation. Biochim. Biophys. Acta. 757:1983;21-28.
19. Marnett L.J., Buck J., Tuttle M.A., Bull A.W. Distribution and oxidation of malondialdehyde in mice. Prostaglandins. 30:1985;241-254.
20. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med. 9:1990;515-540.
21. 2-isoprostanes) in human plasma and isolated low density lipoproteins exposed to metal ion-dependent and -independent oxidative stress. J. Clin. Invest. 93:1994;998-1004.
22. Matthews, W. R.; McKenna, R.; Guido, D. M.; Petre, T. W.; Jolly, R. A.; Morrow, J. D.; Roberts, L. J. A comparison of gas chromatography-mass spectrometry assays for in vivo lipid peroxidation. Proceedings of 41st ASMS Conference Mass Spectrom. Allied Topics 1993:865A-865B.
23. Morrow J.D., Harris T.M., Roberts L.J. Non-cyclooxygenase oxidative formation of a series of novel prostaglandins; Analytical ramifications for measurement of eicosanoids. Anal. Biochem. 184:1990;1-10.
24. 2-isoprostanes) in carbon tetrachloride hepatotoxicity, an animal model of lipid peroxidation. J. Clin. Invest. 90:1992;2502-2507.
25. Roberts L.J., Morrow J.D. Isoprostanes as markers of lipid peroxidation in atherosclerosis. Serhan C.N., Ward P.A., Molecular biology of inflammation. 1999;141-163 Humana Press, Totowa.
26. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. J. Arteriosclerosis Thromb. Vasc. Biol. 17:1997;2975-2981.
27. 2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100:1997;2028-2034.
28. 2-isoprostanes in hypercholesterolemia. Circulation. 98:1998;2822-2828.
29. 2-isoprostanes) in smokers: Smoking as a cause of oxidative damage. N. Engl. J. Med. 332:1198-1203; 1995.
30. Roberts L.J. II. Comparative metabolism and fate of the eicosanoids. Willis A.L., CRC handbook of eicosanoids prostaglandins and related lipids, vol. 1, part A. 1987;239-244 CRC Press, Boca Raton.
31. 2α, is formed in vivo. Biochim Biophys. Acta 1210:244-248; 1994.
32. 2α, in humans. J. Biol. Chem. 271:1996;20617-20620.
33. 2α) by stable isotope dilution mass spectrometric assay. Anal. Biochem.269:326-331; 1999.
34. Reilly M., Delanty N., Lawson J.A., FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 94:1996;19-25.
35. 2-isoprostane levels are increased in patients with Alzheimer's disease. Ann. Neurol. 44:410-413; 1998.
36. 2-isoprostane concentration in probable AD. Neurology. 52:1999;562-565.
37. 2-isoprostanes in Alzheimer's disease evidence for enhanced lipid peroxidation in vivo. FASEB J. 12:1998;1777-1783.
38. 2-isoprostanes, specific markers of lipid peroxidation, are elevated in Huntington's disease patients. Neurology. 52:1999;1104-1105.
39. Pratico D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med. 4:1998;1189-1192.
40. Voutilainen S., Morrow J.D., Roberts L.J. II, Alfthan G., Alho H., Nyssonen K., Salonen J.T. Enhanced in vivo lipid peroxidation at elevated plasma homocysteine levels. Arteriosclerosis Thromb. Vasc. Biol. 19:1999;1263-1266.
41. 2-isoprostanes) in the hepatorenal syndrome. J. Lipid. Mediators 6:417-420; 1993.
42. Stein C.M., Awad J.A., Tanner S.B., Roberts L.J. II, Morrow J.D. Evidence for free radical mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheumat. 39:1996;1146-1150.
43. 2-isoprostanes in aging kidneys. Am. J. Physiol. 274:1998;R767-R774.
44. 2-isoprostanes. J. Nutr. 124:1994;810-864.
45. 2α, on retinal vessels. Am. J. Physiol. 274:1998;R1406-R1416.
46. Nanji A.A., Khwaja S., Tahan S.R., Sadrzadeh S.M. Plasma levels of a novel non-cyclooxygenase derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. J. Pharmacol. Exp. Therap. 269:1994;1280-1285.
47. Alehnik S.I., Leo M.A., Aleynik M.K., Lieber C.S. Increased circulating products of lipid peroxidation in patient with alcoholic liver disease. Alcohol. Clin. Exp. Res. 22:1998;192-196.
48. 2-isoprostanes in atopic asthmatics: Evidence for oxidative stress. Am J. Resp. Crit. Care Med. 160:1947-1951; 1999.
49. 2α and platelet activation in diabetes mellitus effects of improved metabolic control and vitamin E supplementation. Circulation. 99:1999;224-229.
50. Moore K., Patel R., Darley-Usmar V., Holt S., Zackert W.E., Clozel M., Anand R., Wilson M., Harvey S., Morrow J.D., Roberts L.J. II. A causative role for redox cycling of myoglobin and its inhibition by alkalinzation in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J. Biol. Chem. 273:1998;31731-31737.
51. Holt S., Reeder B., Wilson M., Harvey S., Morrow J.D., Roberts L.J. II, Moore K. Increased lipid peroxidation in patients with rhabdomyolysis. Lancet. 353:1999;1241.
52. 2-isoprostane and 4-hydroxynonenal excretion in human bile of patients with biliary tract and pancreatic disorders. Am. J. Gastroenterol. 92:1997;2069-2072.
53. 2 receptor. Kidney Int. 55:1999;271-277.
54. Carpenter C.T., Price P.V., Christman B.W. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury and ARDS. Chest. 114:1998;1653-1659.
55. 2-isoprostanes. Anesthesiology. 84:1996;910-916.
56. Mobert J., Becker B.G. Cyclooxygenase inhibition aggravates ischemia-reperfusion injury in the perfused guinea pig heart involvement of isoprostanes. J. Am. Coll. Cardiol. 31:1998;1687-1694.
57. 2α in acute coronary angioplasty evidence for oxidant stress during coronary reperfusion in humans. Circulation. 96:1997;3314-3320.
58. Mathews W.R., Guido D.M., Fisher M.A., Jaeschke H. Lipid peroxidation as a molecular mechanism of liver cell injury during reperfusion after ischemia. Free Radic. Biol. Med. 16:1994;763-770.
59. 2α, in the rat. J. Clin. Invest. 90:1992;136-141.
60. 2-isoprostanes in vivo by acute Cr (IV) poisoning. Chem. Res. Toxicol. 11:1998;1516-1520.
61. Awad J.A., Burk R.F., Roberts L.J. II. Effect of selenium deficiency and glutathione modulating agents on diquat toxicity and lipid peroxidation. J. Pharmac. Exp. Therap. 270:1994;858-864.
62. 2-isoprostane production and injury in renal tubular epithelial cells. J Am. Soc. Nephrol.9:1448-1455; 1998.
63. 2-isoprostane formation in renal tubular cells and rat kidneys stored in University of Wisconsin solution: Implications for immediate post-transplant renal vasoconstriction. Kidney Int. 55:1759-1762; 1999.
64. Pratico D., Basili S., Vieri M., Cordova C., Violi V., Fitzgerald G.A. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-II, an index of oxidant stress. Am. J. Resp. Crit. Care Med. 158:1998;1709-1714.
65. Montuschi, P.; Ciabattoni, G.; Paredi, P.; Pantelidis, P.; DuBois, R. M.; Kharitoniv, S. A.; Barnes, P. J. 8-isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J. Resp. Crit. Care Med. 158:1524-1527; 1998.
66. 2-isoprostanes in diisopropylfluorophosphate induced muscle hyperactivity. Biochem. Pharmacol. 52:357-361; 1996.